Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | GALK1 | P51570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1040796 | 1.00 | RAB9A (0.39) | RAB9ANPC1SIRT2ALDH1A1SMN1; SMN2 | |
| SCHEMBL8070031 | 0.83 | ALDH1A1 (0.49) | SIRT2ALDH1A1LMNAMAPTGABRA2 | |
| SCHEMBL9060018 | 0.82 | SIRT2 (0.41) | SIRT2ALDH1A1L3MBTL1LMNAMAPT | |
| SCHEMBL9789313 | 0.79 | SIRT2 (0.42) | SIRT2ALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL28361973 | 0.79 | NPC1 (0.51) | RAB9ANPC1SIRT2ALDH1A1CASP3 | |
| SCHEMBL5266089 | 0.77 | SIRT2 (0.41) | SIRT2ALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL1040045 | 0.77 | CYP11B1 (0.41) | SIRT2ALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL1414901 | 0.76 | SIRT2 (0.40) | SIRT2SMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL9263509 | 0.74 | MAPT (0.46) | RAB9ANPC1SIRT2MAPT | |
| SCHEMBL9263513 | 0.74 | MAPT (0.46) | RAB9ANPC1SIRT2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278969-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-20140357621-A1 | Organic Compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| EP-2256118-B1 | Condensed imidazolo derivatives for the inhibition of aromatase and the treatment of aldosterone related diseases | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8835646-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| US-20130287789-A1 | Organic Compounds | NOVARTIS AG (CH) | 2013-10-31 | — | — | US | disclosed |
| EP-1919916-B1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-8314097-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20120277215-A1 | Organic Compounds | RECORDATI AG (CH) | 2012-11-01 | — | — | US | disclosed |
| EP-2270011-A1 | Condensed imidazolo derivatives for the inhibition of aromatase | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-2256118-A1 | Condensed imidazolo derivatives for the inhibition of aromatase | Novartis AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049616-A1 | Organic compounds | CYP19A1, CYP17A1, HSD17B11 | RAB9A 3940/4885NPC1 2328/4885SIRT2 2715/4885 |
| US-20130287789-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | RAB9A 3940/4885NPC1 2328/4885SIRT2 2715/4885 |
| US-20120277215-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | RAB9A 3940/4885NPC1 2328/4885SIRT2 2715/4885 |
| US-20140357621-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | RAB9A 3940/4885NPC1 2328/4885SIRT2 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.